Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ModCAR-Mesothelin
- Development stage
- Preclinical
- Lead developer
- Hauul Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ModCAR-Mesothelin is a preclinical-stage modular chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio for the treatment of mesothelin-expressing solid tumors. The therapy utilizes Hauul Bio's proprietary ModCAR platform, which features a modular design intended to provide greater control over CAR-cell activity and reduce the risk of off-tumor toxicities. The program is currently being evaluated for indications including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). By targeting mesothelin, a cell-surface glycoprotein overexpressed in various malignancies, ModCAR-Mesothelin aims to provide a potent and selective therapeutic option for patients with difficult-to-treat solid tumors.
- Other names
- ModCAR-Mesothelin
02
Targets
Mesothelin
Beyond the preview
Go deeper on ModCAR-Mesothelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ModCAR-Mesothelin.